Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 30Unknown 16Terminated 6Not yet recruiting 4Recruiting 3Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Myeloid 1Genitourinary 1

Conditions

Breast Neoplasms 848Carcinoma, Non-Small-Cell Lung 549Neoplasms 510Prostatic Neoplasms 501Lung Neoplasms 312Colorectal Neoplasms 307Multiple Myeloma 292Neoplasm Metastasis 250Melanoma 241Ovarian Neoplasms 215Leukemia, Myeloid, Acute 208Pancreatic Neoplasms 207Squamous Cell Carcinoma of Head and Neck 173Carcinoma, Renal Cell 165Recurrence 162Stomach Neoplasms 161Carcinoma, Hepatocellular 160Lymphoma 156Brain Neoplasms 152Glioblastoma 147Uterine Cervical Neoplasms 144Lymphoma, Non-Hodgkin 141Head and Neck Neoplasms 140Triple Negative Breast Neoplasms 136Leukemia, Lymphocytic, Chronic, B-Cell 136Urinary Bladder Neoplasms 135Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Colonic Neoplasms 115Hematologic Neoplasms 113Lymphoma, Follicular 112

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Hypersensitivity × Clear all
NCT05186753 2026-05-22

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Cogent Biosciences, Inc.

Phase 2 Active not recruiting
237 enrolled
Myeloid

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Mastocytosis, Mastocytosis, Systemic

NCT07511517 2026-04-09

BladMetrix

Oslo University Hospital

Active not recruiting
500 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Hypersensitivity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡